Help patients get going at no cost with AUSTEDO XR

Patients can start and stay on track with once-daily AUSTEDO XR1,2

Titration Kits help patients adhere through the first 4 weeks and achieve treatment success.2* See details from the real-world START study

In a real-world study assessing 4-week Titration Kit use2†:

  • ~80% of patients reached ≥24 mg/day by Week 4
  • 97% of patients adhered to Titration Kit
  • Patients and physicians reported treatment success consistent with the pivotal studies* 

Patients in the START study used the AUSTEDO BID 4-week Titration Kit.

AUSTEDO XR 4-week Titration Kit.

Two ways to get patients started for free with the 4-week Titration Kit:

Sample with Titration Kit
And prescribe 36 mg/day for Week 51

Blister packs for AUSTEDO XR 4-week Titration Kit.

(ask your sales representative for 4-week Titration Kit samples)

Prescribe Titration Kit (NDC: 68546-0490-52)
And use 30-day Free Trial Voucher§

AUSTEDO XR 4-week Titration Kit and 30-day Free Trial Voucher for new patients. This Free Trial Voucher is not conditioned on any past, present, or future purchase, including refills. No purchase is required.
Blister packs for AUSTEDO XR 4-week Titration Kit.

(provide a second prescription at 36 mg/day for Week 5 with initial prescription)1

Continue titrating weekly until symptom control is effectively and tolerably achieved (48 mg/day maximum dosage).1

For continuing patients: Write once-daily AUSTEDO XR for their next refill (at same total daily dose as AUSTEDO BID)1

Insurance codes

ICD-10 CM Diagnosis Code: G24.01 Tardive Dyskinesia (TD)



10-digit NDC

11-digit NDC


6 mg

12 mg

24 mg








10-digit NDC

11-digit NDC

Titration Kit




Teva Shared Solutions®.

Use the Prescription & Service Request Form (PSRF) to get started with the support of Teva Shared Solutions®

Financial assistance offerings available: some
patients may pay $10 or less per month for AUSTEDO2

Learn more about cost and coverage

Additional resources to help with patient access:

*Based on Patient Global Impression of Change and Clinical Global Impression of Change.2

The START study was a non-interventional, real-world study assessing 4-week Titration Kit utilization and treatment success in 50 patients of similar demographics to the AUSTEDO tardive dyskinesia pivotal studies.2

Notify pharmacy if patient has been sampled.

§Request pharmacy apply 30-day Free Trial Voucher against initial 30-day Rx. Certain restrictions apply. Terms and conditions on

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.